JP2014505056A5 - - Google Patents

Download PDF

Info

Publication number
JP2014505056A5
JP2014505056A5 JP2013548613A JP2013548613A JP2014505056A5 JP 2014505056 A5 JP2014505056 A5 JP 2014505056A5 JP 2013548613 A JP2013548613 A JP 2013548613A JP 2013548613 A JP2013548613 A JP 2013548613A JP 2014505056 A5 JP2014505056 A5 JP 2014505056A5
Authority
JP
Japan
Prior art keywords
antibody
tlr4
immunologically active
active fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013548613A
Other languages
English (en)
Japanese (ja)
Other versions
JP6289098B2 (ja
JP2014505056A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/020717 external-priority patent/WO2012096917A1/en
Publication of JP2014505056A publication Critical patent/JP2014505056A/ja
Publication of JP2014505056A5 publication Critical patent/JP2014505056A5/ja
Application granted granted Critical
Publication of JP6289098B2 publication Critical patent/JP6289098B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013548613A 2011-01-10 2012-01-10 抗ｔｌｒ４抗体およびその使用法 Active JP6289098B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161431191P 2011-01-10 2011-01-10
US61/431,191 2011-01-10
PCT/US2012/020717 WO2012096917A1 (en) 2011-01-10 2012-01-10 Anti-tlr4 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017027473A Division JP2017137319A (ja) 2011-01-10 2017-02-17 抗ｔｌｒ４抗体およびその使用法

Publications (3)

Publication Number Publication Date
JP2014505056A JP2014505056A (ja) 2014-02-27
JP2014505056A5 true JP2014505056A5 (enExample) 2015-02-26
JP6289098B2 JP6289098B2 (ja) 2018-03-07

Family

ID=46455425

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013548613A Active JP6289098B2 (ja) 2011-01-10 2012-01-10 抗ｔｌｒ４抗体およびその使用法
JP2017027473A Pending JP2017137319A (ja) 2011-01-10 2017-02-17 抗ｔｌｒ４抗体およびその使用法
JP2019035074A Pending JP2019081796A (ja) 2011-01-10 2019-02-28 抗ｔｌｒ４抗体およびその使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017027473A Pending JP2017137319A (ja) 2011-01-10 2017-02-17 抗ｔｌｒ４抗体およびその使用法
JP2019035074A Pending JP2019081796A (ja) 2011-01-10 2019-02-28 抗ｔｌｒ４抗体およびその使用法

Country Status (7)

Country Link
US (4) US8734790B2 (enExample)
EP (2) EP3539987A1 (enExample)
JP (3) JP6289098B2 (enExample)
AU (2) AU2012205763B2 (enExample)
CA (1) CA2824060C (enExample)
ES (1) ES2721378T3 (enExample)
WO (1) WO2012096917A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009101479A2 (en) * 2007-05-14 2009-08-20 Novimmune Sa Fc receptor-binding polypeptides with modified effector functions
ES2721378T3 (es) * 2011-01-10 2019-07-31 Novimmune Sa Anticuerpos anti-TLR4 y métodos de uso de los mismos
JP6419064B2 (ja) * 2012-03-29 2018-11-07 ノビミューン エスアー 抗ｔｌｒ４抗体およびその使用
AU2014338991B2 (en) 2013-10-22 2020-06-11 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
CA2932787A1 (en) * 2013-12-06 2015-06-11 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof
EP3332256A1 (en) * 2015-08-06 2018-06-13 NovImmune SA Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
CN109481666B (zh) * 2018-12-21 2020-11-03 江苏省中医院 一种人体血液肿瘤pdx模型的建立方法
CA3174429A1 (en) * 2020-04-20 2021-10-28 Edesa Biotech Research Inc. Compositions and methods for treatment of acute respiratory distress syndrome
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
PL377091A1 (pl) * 2002-09-06 2006-01-23 Amgen, Inc. Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
ES2382039T3 (es) 2003-12-10 2012-06-04 Novimmune Sa Anticuerpos anti-TLR4/MD-2 neutralizantes y métodos de uso de los mismos
US7674884B2 (en) 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
EP3476861A1 (en) * 2004-01-07 2019-05-01 Novartis Vaccines and Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
AU2006297259A1 (en) 2005-09-30 2007-04-12 Oklahoma Medical Research Foundation Regulation of toll-like receptors on stem cells
WO2009101479A2 (en) * 2007-05-14 2009-08-20 Novimmune Sa Fc receptor-binding polypeptides with modified effector functions
US8202650B2 (en) 2007-07-24 2012-06-19 Panasonic Corporation Negative electrode material for nickel-metal hydride battery and treatment method thereof, and nickel-metal hydride battery
WO2009138494A2 (en) 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
NZ591471A (en) * 2008-08-18 2012-08-31 Pfizer Antibodies to ccr2
ES2721378T3 (es) * 2011-01-10 2019-07-31 Novimmune Sa Anticuerpos anti-TLR4 y métodos de uso de los mismos

Similar Documents

Publication Publication Date Title
JP2014505056A5 (enExample)
AU2019246821B2 (en) Anti-cd40 antibodies and uses thereof
JP2025139586A (ja) ヒトのがんを治療するための特異的抗ｃｄ３８抗体
Shrestha et al. Historical perspectives in kidney transplantation: an updated review
JP2025106512A (ja) 調節性ｔ細胞及びその使用
BR112018009972B1 (pt) Ligante de ctla4, ligante, recipiente ou dispositivo de injeção, polinucleotídeo, vetor, célula hospedeira, métodos para fabricar o ligante de ctla4 e para prevenir que ctla4 se ligue à cd80 ou cd86 e usos do referido ligante de ctla4
WO2012125680A1 (en) Methods of treating vasculitis using an il-17 binding molecule
RU2017118985A (ru) Антитела, их применение и способы применения
JP2019517498A (ja) 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体
JP2022163078A (ja) 移植片対宿主病予防の方法
JP2025118642A (ja) 移植片対宿主病の処置または予防の方法
CA3114922A1 (en) Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
US12221479B2 (en) Pharmaceutical combination of anti CEACAM6 and TIM3 antibodies
WO2022109302A9 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
CN116782934A (zh) 抗半乳糖凝集素9抗体及其在治疗眼部黑素瘤中的用途
JP7621943B2 (ja) がんを治療するための、抗ｃｅａｃａｍ６および抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体のいずれかの医薬組み合わせ
US20240228654A9 (en) Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
JPWO2023036745A5 (enExample)
CN120225561A (zh) 用于癌症新辅助治疗的包含抗cd39抗体的组合物和方法
CN116997570A (zh) 用于治疗抗体介导的移植排斥的抗cd38抗体
HK40069657B (zh) 抗半乳糖凝集素-9 抗体及其用途
HK40048141B (zh) 抗ceacam6和tim3抗体的药物组合
EA041816B1 (ru) Способ профилактики болезни "трансплантат против хозяина"